Found 12 clinical trials
LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib
To determine whether in patients with EGFR mutated advanced NSCLC and osimertinib as first-line treatment, the (repeated) use of LAT to 3 OP lesions and continuation of first-line osimertinib, improves the median progression-free survival by more than 3 months (i.e. PFS2-PFS1 = >3 months).
- 0 views
- 16 Feb, 2024
- 1 location
Real-life Pan-HER-blockade With Neratinib
So far, there is no data available on treatment of patients with early-stage hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2)-overexpressed/amplified breast cancer, who completed adjuvant trastuzumab-based therapy less than one year ago, in the clinical routine setting.
- 0 views
- 05 Aug, 2020
- 1
- 2